Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR7163]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(6 Publications)
Rabbit Recombinant Monoclonal Sumo 2 antibody. Suitable for WB, ICC/IF, Flow Cyt (Intra) and reacts with Human samples. Cited in 6 publications.
View Alternative Names
SMT3B, SMT3H2, SUMO2, Small ubiquitin-related modifier 2, SUMO-2, HSMT3, SMT3 homolog 2, SUMO-3, Sentrin-2, Ubiquitin-like protein SMT3B, Smt3B, SMT3A, SMT3H1, SUMO3, Small ubiquitin-related modifier 3, SUMO-3, SMT3 homolog 1, SUMO-2, Ubiquitin-like protein SMT3A, Smt3A, SMT3H4, SUMO4, Small ubiquitin-related modifier 4, SUMO-4, Small ubiquitin-like protein 4
- ICC/IF
Unknown
Immunocytochemistry/ Immunofluorescence - Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR7163] (AB126606)
ab126606 at 1/250 dilution staining Sumo 2 + Sumo 3 + Sumo 4 in HepG2 (Human liver hepatocellular carcinoma cell line) cells by immunofluorescence.
- Flow Cyt (Intra)
Unknown
Flow Cytometry (Intracellular) - Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR7163] (AB126606)
Overlay histogram showing HEK293 cells stained with ab126606 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab126606, 1/1000 dilution) for 30 min at 22°C. The secondary antibody used was Alexa Fluor® 488 goat anti-rabbit IgG (H&L) (ab150077) at 1/2000 dilution for 30 min at 22°C. Isotype control antibody (black line) was rabbit IgG (monoclonal) (0.1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter.
- WB
Unknown
Western blot - Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR7163] (AB126606)
All lanes:
Western blot - Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR7163] (ab126606) at 1/10000 dilution
Lane 1:
HepG2 cell lysate at 10 µg
Lane 2:
293T cell lysate at 10 µg
Lane 3:
Jurkat cell lysate at 10 µg
Lane 4:
Human spleen tissue lysate at 10 µg
Secondary
All lanes:
Goat anti-Rabbit HRP at 1/2000 dilution
Predicted band size: 11 kDa
false
- WB
Lab
Western blot - Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR7163] (AB126606)
Blocking buffer : 5% NFDM/TBST
All lanes:
Western blot - Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR7163] (ab126606) at 1/5000 dilution
Lane 1:
Western blot - Recombinant Human Sumo 1 protein (<a href='/en-us/products/proteins-peptides/recombinant-human-sumo-1-protein-ab140417'>ab140417</a>) at 0.01 µg
Lane 2:
Western blot - Recombinant Human Sumo 2 protein (<a href='/en-us/products/proteins-peptides/recombinant-human-sumo-2-protein-ab140420'>ab140420</a>) at 0.01 µg
Lane 3:
Recombinant Human Sumo 3 protein (<a href='/en-us/products/unavailable/recombinant-human-sumo-3-protein-ab140414'>ab140414</a>) at 0.01 µg
Lane 4:
Western blot - Recombinant Human Sumo 4 protein (<a href='/en-us/products/proteins-peptides/recombinant-human-sumo-4-protein-ab157025'>ab157025</a>) at 0.1 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 11 kDa
Observed band size: 16 kDa
true
Exposure time: 3s
- OI-RD Scanning
Unknown
OI-RD Scanning - Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR7163] (AB126606)
We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody. Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.
Related conjugates and formulations (1)
-
Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR7163] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purity
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Through the attachment to target proteins these SUMO proteins influence various cellular processes like nuclear-cytosolic transport transcriptional regulation and DNA repair. SUMO-2 and SUMO-3 often act as part of a complex with other SUMO proteins enhancing their functional diversity. SUMOylation can alter protein-protein interactions and stabilize protein structure impacting gene expression and cellular response to stress. SUMO-4 due to a unique proline residue shows distinct regulatory functions particularly in stress responses and immune reactions.
Pathways
Protein SUMOylation plays an important role in major signaling pathways such as the NF-kB and p53 pathways. SUMO-2 and SUMO-3 modification can regulate the activity of p53 an important transcription factor in cell cycle control and apoptosis. Their association with the NF-kB pathway influences inflammatory responses. Importantly these modifications can affect proteins like IκBα and MDM2 which are directly involved in regulating NF-kB and p53 activities showing their involvement in maintaining cellular homeostasis and stress responses.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Additional targets
Publications (6)
Recent publications for all applications. Explore the full list and refine your search
Cells 12: PubMed36980166
2023
Applications
Unspecified application
Species
Unspecified reactive species
Molecular medicine reports 27: PubMed36601740
2023
Applications
Unspecified application
Species
Unspecified reactive species
Journal of neurology 269:4863-4871 PubMed35503374
2022
Applications
Unspecified application
Species
Unspecified reactive species
Oncology letters 20:225 PubMed32968447
2020
Applications
Unspecified application
Species
Unspecified reactive species
eLife 8: PubMed30652970
2019
Applications
Unspecified application
Species
Unspecified reactive species
Molecular medicine reports 17:1283-1288 PubMed29115559
2017
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com